Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 16-Week, Open-Label, Multi-Center, Parallel, Randomized Controlled Study to Compare the Safety, Tolerability, Pharmacokinetics and Efficacy of Slow and Rapid Dose Titration Regimens of Subcutaneous Remodulin Therapy in Subjects With Pulmonary Arterial Hypertension

NCT02893995 is registered in ClinicalTrials.gov with United Therapeutics as lead sponsor.

NCT NCT02893995
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02893995 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 16-Week, Open-Label, Multi-Center, Parallel, Randomized Controlled Study to Compare the Safety, Tolerability, Pharmacokinetics and Efficacy of Slow and Rapid Dose Titration Regimens of Subcutaneous Remodulin Therapy in Subjects With Pulmonary Arterial Hypertension
Lead sponsor
United Therapeutics
Phase
Phase 4
Overall status
Withdrawn
Start date
February 28, 2017
Completion date
April 30, 2018
Enrollment
0 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary arterial hypertension